Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 15, 2017 09:35 ET | Source: Motif BioSciences Inc.

Motif Bio announces iclaprim granted Orphan Drug Designation by US FDA for treatment of Staphylococcus aureus lung infections in patients with cystic fibrosis

NEW YORK, Sept. 15, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (Nasdaq:MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the...
September 08, 2017 08:00 ET | Source: Motif BioSciences Inc.

Motif Bio to Host Investor and Analyst Event on September 20, 2017 in New York

NEW YORK, Sept. 08, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (Nasdaq:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announces that the...
August 31, 2017 08:00 ET | Source: Motif BioSciences Inc.

Motif Bio to present at upcoming investor and scientific conferences

NEW YORK, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that...
August 14, 2017 08:30 ET | Source: Motif BioSciences Inc.

Motif Bio to Present at the 7th Annual Trout Group Hamptons CEO Roundtable Conference on August 17th

NEW YORK, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB) ("Motif" or the "Company"), the clinical stage biopharmaceutical company specializing in developing novel...
August 09, 2017 02:00 ET | Source: Motif BioSciences Inc.

Motif Bio’s second Phase 3 clinical trial in ABSSSI finishes patient treatment phase

NEW YORK, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that...
July 06, 2017 02:00 ET | Source: Motif BioSciences Inc.

Motif Bio to Present Three Posters at IDWeek 2017

NEW YORK, July 06, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (NASDAQ:MTFB) (AIM:MTFB.LN), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced that...
June 22, 2017 18:31 ET | Source: Motif BioSciences Inc.

Motif Bio Announces Result of General Meeting and Total Voting Rights

THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFERING OF ANY SECURITIES. ANY OFFERING OF SECURITIES BY THE COMPANY IS NOT ADDRESSED TO ANY PERSON WITH A REGISTERED ADDRESS IN, OR WHO IS RESIDENT IN, THE...
June 22, 2017 02:00 ET | Source: Motif BioSciences Inc.

Motif Bio Invited to Present at Infectious Diseases Conference

NEW YORK, June 22, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (NASDAQ:MTFB)(AIM:MTFB.LN), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced that...
June 14, 2017 02:00 ET | Source: Motif BioSciences Inc.

Motif Bio to Present at BIO International Convention

NEW YORK, June 14, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (NASDAQ:MTFB) (AIM:MTFB.LN), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced that...
May 18, 2017 02:00 ET | Source: Motif BioSciences Inc.

Publication of UK Annual Report and Accounts & Notice of AGM

NEW YORK, May 18, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (NASDAQ:MTFB) (AIM:MTFB.LN), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced its...